Table 1.
Primary antibody | Isotype control | ||||
---|---|---|---|---|---|
Target | Clone | Label | Target | Clone | Label |
human CD105 | 43A4E1 | PE *1 | mouse IgG1 | IS5-21F5 | PE |
human CD73 | AD2 | PE | mouse IgG1 | IS5-21F5 | PE |
human CD90 | DG3 | PE | mouse IgG1 | IS5-21F5 | PE |
human CD146 | 541-10B2 | PE | mouse IgG1 | IS5-21F5 | PE |
human CD45 | 5B1 | PE | mouse IgG2a | S43.10 | PE |
human CD34 | AC136 | PE | mouse IgG2a | S43.10 | PE |
human CD14 | REA599 | PE | mouse IgG2a | S43.10 | PE |
human CD79 | HM47 | PE | mouse IgG1 | IS5-21F5 | PE |
human HLA-DR | IS5-20C4 | PE | mouse IgG2a | S43.10 | PE |
human STRO-1 | STRO-1 | *2 | mouse IgM | IS5-20C4 | PE |
*1: PE phycoerythrin
*2: Anti-human STRO-1 antibody was labelled with PE-conjugated anti-mouse IgM secondary antibody (clone: REA979)
Anti-human STRO-1antibody was purchased by R&D Systems, MN, USA, and other antibodies were purchased by Miltenyi Biotec, North Rhine-Westphalia, Germany